Keywords
Rehabilitation
RheumatoidarthritiS
How to Cite
Abstract
Rheumatoid arthritis is a chronic autoimmune disease that affects the body's joints. The exact cause of rheumatoid arthritis is not completely understood, but it is considered an autoimmune disease in which the immune system attacks the body itself. General Objective: to present scientific material that covers a detailed study on the origin, causes and evolution of Rheumatoid Arthritis (RA), as well as to identify the most used approaches in physiotherapeutic treatment. Methodology: This is a bibliographic review. Consultations with research indexers in the databases were: MEDLINE/PubMed, SciELO and LILACS, covering the period from January 2017 to December 2023. Results and Discussion: The initial research resulted in 137 results, of which only 10 met the selection criteria established for the preparation of the bibliographic review. The pathophysiology of rheumatoid arthritis (RA) is complex and involves several immunological and inflammatory processes that lead to chronic joint inflammation and, eventually, the destruction of joint tissue. Final Considerations: Physiotherapy plays a significant role in the rehabilitation of patients with rheumatoid arthritis (RA), providing a series of important benefits to reduce symptoms, especially pain, in addition to improving functionality and quality of life.
References
KNEVEL, R.; HUIZINGA, T.W.J.; KURREEMAN, F. Genomic Influences on Susceptibility and Severity of Rheumatoid Arthritis. Rheumatic Disease Clinics of North America. 2017.
LOPES, A.B.L.G. Imunoterapia e artrite reumatoide. Monografia (Mestrado Integrado em Ciências Farmacêuticas) - Universidade de Lisboa, Lisboa, 2019;
SOCIEDADE BRASILEIRA DE REUMATOLOGIA. Artrite Reumatoide. Doença inflamatória crônica que pode afetar várias articulações e com causa ainda desconhecida. 2021.
SCHULERT, G.S.M.F.; et al. Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activati on Syndrome Associated With Systemic Juvenil eI diopathic Arthritis. Arthritis Care Res (Hoboken). 2018;70(3):409-19.
SHENOI S.H.G.; et al. The burden of systemic juvenile idiopathic arthritis for patients and care givers: An international survey and retrospective chart review. Clin Exp Rheumatol. 2018;36(5):920-8.
SOTA, J.I.A.; et al. Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis. Front Pharmacol. 2019;9(1526).
HORNEFF. G.S.A.; et al. Experience withet an ercept, tocilizumab and interleukin-1 inhibitors in systemic on set juvenile idiopathic arthritis patients from the BIKER registry. Arthritis Res Ther. 2017;19(1):256.
MEZZARI, M.A.J.M.C.; et al. Avaliação da amplitude de movimento na Artrite Reumatoide: uma revisão de literatura/Motion range assessment in Rheumatoid Arthritis: a literature review. Cadernos Brasileiros De Terapia Ocupacional, 25(2), 387–400. 2017.
SHENOI, S.H.G.; et al. The disease burden of systemic juvenile idiopathic arthritis for patients and care givers: An international health related quality of life survey and retrospective chart review. Annal soft her heumatic diseases. 2017;76(Suppl2).
BRUNNER, H.R.N.; et al. Efficacy and safety of canakinumab in patients with systemic juvenile idiopathic arthritis: Results from an open- label, long-term follow-up study. 2017.
RUPERTO, N.B.H.; et al. Efficacy and safety of canakinumab in patients with systemic juvenile idiopathic arthritis: Results from an open- label, long-term follow-up study. 2017;15(0).
HORNEFF, G.S.A.; et al. Efficacy comparison with tocilizumab, interleukin-1 inhibitors and etanercept for treatment of systemic juvenile idiopathic arthritis. Annal soft he Rheumatic Diseases. 2017;75(0):270-1.
WOERNER, A.U.F.; et al. Biological treatment in systemic juvenil eidiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent. RMD open. 2017;1(1): e000036.
CABRERA, N.L.J.; et al. Safety of biological agents in paediatric rheumatic diseases: A real-life multicenter retrospective study using the JIR cohort database. . Joint, bone, spine: revue dur humatisme. 2018.
TARP, S.A.G.; et al. Efficacy and safe ty of biological agents for systemic juvenile idiopathic arthritis: A systematic review and meta-analysis of randomized trials ;74:391-2. Annal soft her reumatic diseases. 2017; 74:391-2.
OTTEN, M.H.A.J.; et al. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons 72(11):1806-12. Annal soft her heumatic diseases. 2017;72(11):1806-12.
RINGOLD, S.W.P.; et al. 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis. Arthritis and Rheumatism. 2017;65(10):2499-512.
MOTA, L.M.H.; et al. Guidelines for the drug treatment of rheumatoid arthritis. Ver Bras Reumatol. 2017 Apr;53(2):158–83.
BRASIL. Manual de recomendações para o Controle da Artrite Reumatóide no Brasil. Ministério da Saúde. 2019.
GERMANO, J.L.; et al. Prevalência da artrite reumatoide na América do Sul: revisão sistemática e meta-análise. FREE THEMES, Ciênc. saúde coletiva 26 (suppl 3), 2021.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Orivaldo Pereira Melo, Jessica Evangelista de Macêdo, Raquel Cabral Moraes, Pabloena da Silva Pereira